Phantpep Bio Completes Tens of Millions RMB Series A Financing to Accelerate Development and Clinical Adoption of Innovative Immune Function Precision Assessment Solutions

Recently, Fantai Biotechnology (Zhejiang) Co., Ltd. (“Fantai Bio”) announced the completion of its Series A financing round, raising tens of millions of yuan. The round was exclusively invested by YuanBio Venture Capital, with Qushi Capital serving as the exclusive financial advisor. The funds raised will be primarily used to support the company’s continued R&D and market expansion of its flow cytometry technology platform, providing comprehensive solutions for precise assessment of immune function in clinical patients.

PanTai Biotech’s ability to achieve its current performance in a short period and rapidly grow into a benchmark enterprise in the field of flow cytometry is closely tied to its seasoned team with extensive IVD experience. The company’s founding team has many years of experience in the medical industry, possesses an in-depth understanding of market development within the healthcare sector, and holds abundant customer resources. The R&D team has been deeply engaged in flow cytometry and related fields for many years, accumulating rich experience in the research and industrialization of flow cytometry-related reagents and instruments.

Currently, the clinical flow cytometry testing market in China has reached a scale of several billion RMB and maintains a high annual growth rate of over 30%. International giants such as BD and Beckman continue to dominate the domestic clinical flow cytometry testing market, leveraging their advanced technologies, superior products, and substantial investments in the clinical sector. Although numerous Chinese flow cytometry companies have emerged in recent years and are striving to catch up, it remains highly challenging to capture market share from these international leaders solely through lower pricing. Achieving overtaking on a bend will inevitably require a focus on innovative product development.

Lymphocyte subset analysis is one of the primary clinical applications of flow cytometry, mainly used to assess patients’ immune function and guide clinical diagnosis and medication. However, clinicians often find that lymphocyte subset testing provides only quantitative information on immune cells, without indicating their quality or activity, thus limiting the precision of immune function assessment. To address this clinical need, PanPeptide Bio spent five years in research and development and successfully created core reagents and algorithmic software capable of simultaneously measuring both the quantity and activity of immune cells, enabling more precise evaluation of immune function. In June 2022, the product received China’s first in vitro diagnostic (IVD) certificate for mitochondrial detection in immune cells. PanPeptide Bio aims to break the long-standing dominance of imported products in the flow cytometry market by offering a portfolio of exclusive, innovative flow cytometry assays represented by this product. This round of financing will support the company in accelerating this process.

Mr. He Miao, Founder and Chairman of FanTai BioStatement: It is a great honor to receive recognition from the investors at YuanBio Venture Capital. The substantial financial support will enable us to attract more talent, increase R&D investment, and accelerate the industrialization of our products. Over the next two decades, China’s in vitro diagnostics (IVD) industry will be an innovation-driven market, with originality and innovative capacity serving as the core drivers for enterprise growth. Moving forward, Pante Bio will continue to advance the development of foundational technologies and the construction of testing systems, accelerate the clinical promotion and application of Pante Bio’s immune cell mitochondrial detection products, and bring about revolutionary changes to the domestic flow cytometry market. We will continuously iterate and evolve to provide patients with more innovative technologies, products, and services.

Dr. Lin Yi, Managing Partner at YuanBio Venture CapitalStatement: Currently, international brands still hold a monopoly in the field of clinical flow cytometry testing. A major reason for this is the lack of innovative products from domestic brands that can better meet clinical needs. Based on keen clinical observations, PanTide Bio identified unmet clinical demands and, through years of independent research and development, has created innovative flow cytometry products. These products are poised to address unmet clinical needs and open up new opportunities for domestic substitution. Furthermore, we highly recognize the all-in commitment and efficient execution capabilities of the founding team. We believe that the collaboration between YuanBio Venture Capital and PanTide Bio will not only provide financial support to help the company continue its growth and expansion but also bring greater assistance in terms of upstream and downstream industry resources and strategic layout. We look forward to working with the company to accelerate the process of domestic substitution and innovative R&D in clinical flow cytometry testing.

PanTai Bio was established in 2017 with a commitment to becoming a global leader in the precise assessment of human immune system function. Leveraging flow cytometry technology, the company continuously develops innovative flow cytometry diagnostic reagents and instruments that better meet clinical needs, providing comprehensive solutions for the precise evaluation of immune status across multiple scenarios, including infections, autoimmune diseases, and tumors, for healthcare institutions. Supported by the profound technical expertise of its core founding team and the relentless efforts of its R&D team, PanTai Bio has achieved rapid progress. The company now holds more than 20 core invention patents and has successfully developed multiple innovative flow cytometry reagents and instruments. Notably, its innovative kits for detecting immune cells and their mitochondria, along with the accompanying flow cytometers, have obtained the first IVD registration certificate in China for products of their kind. Adopting a dual-driven business model combining third-party outsourced testing and in-hospital reagent sales, PanTai Bio has partnered with over one hundred renowned hospitals and research institutions. This approach has better addressed unmet clinical needs and driven rapid growth in sales performance. Looking ahead, the company will use Zhejiang Province and other regions as its foundation to rapidly expand its presence across China.

YuanBio Venture Capital is an investment firm focused on the early and growth stages of the healthcare sector, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 160 outstanding companies in the life and health industries, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 16 of its portfolio companies having listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanBio Venture Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. By bringing together seasoned professional investors and a team of world-class scientific advisors, YuanBio possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, YuanBio is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.